CEL-SCI Corp (CVM)
CEL-SCI Corp is a clinical-stage biotechnology company listed on the NYSE under the ticker CVM. The company focuses on immunotherapy research and development for cancer and other diseases. Its lead candidate, Multikine, has completed Phase III clinical trials for use in certain head and neck cancers. CEL-SCI is also advancing its LEAPS platform, a patented T-cell modulation technology being studied across areas such as infectious diseases, autoimmune disorders, allergies, transplant rejection, and cancer. The company’s LEAP candidates, including CEL-2000, CEL-4000, and CEL-5000, are in preclinical development for possible rheumatoid arthritis treatment. CEL-SCI also has a strategic partnership with Saudi Arabian Pharma Company related to Multikine in head and neck cancer. The company was incorporated in 1983 and is based in Vienna, Virginia.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-CVM
|
$1.76
|
39.5% Upside
|
Undervalued
|
$15 1,085.8% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-1.0x
|
3.2x
|
—
|
22.196 M
|
28.81 M
|
27.7%
|
96.8%
|
-46.8
|
—
|
73.4%
|
